|Videos|April 20, 2018
There Are Multiple Dynamic Biomarkers for Bladder Cancer
Author(s)Padmanee Sharma, M.D., Ph.D.
While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.
Advertisement
When it comes to biomarkers used to determine treatment strategy in bladder cancer, there is more than PD-1, PD-L1 and CTLA-4, says Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Researchers have not yet examined or reached a full understanding of all the possible checkpoints, especially since the targets — like the immune response in general – are very dynamic and change over time.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Advisory Committee Backs RP1 for Advanced Melanoma
2
Living With Lung Cancer, Not Dying From It: One Survivor's Story of Hope
3
Same-Day Discharge and Single-Incision Surgery Are Changing Rectal Cancer Care
4
Oncology Researcher Brings Science, Compassion and Personal Loss to Cancer Care
5